Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk - PubMed (original) (raw)
. 2000 Mar 1;92(5):412-7.
doi: 10.1093/jnci/92.5.412.
Affiliations
- PMID: 10699071
- DOI: 10.1093/jnci/92.5.412
Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk
D Xie et al. J Natl Cancer Inst. 2000.
Abstract
Background: Alterations of the HER2 (also known as erbB-2 or neu) proto-oncogene have been implicated in the carcinogenesis and prognosis of breast cancer. A polymorphism at codon 655 (GTC/valine to ATC /isoleucine [Val(655)Ile]) in the transmembrane domain-coding region of this gene has been identified and may be associated with the risk of breast cancer. We evaluated this hypothesis in a subgroup of women who participated in a large-scale, population-based, case-control study of breast cancer in Shanghai, China.
Methods: Genomic DNA from 339 patients with breast cancer and 361 healthy control subjects was examined for the Val(655)Ile polymorphism with a polymerase chain reaction-restriction fragment-length polymorphism-based assay. All study subjects completed a structured questionnaire during an in-person interview. All P values are from two-sided tests.
Results: We found that 25.1% of the case patients and 21.7% of the control subjects were heterozygous for the Val allele and 3.2% of the case patients and 0. 3% of the control subjects were homozygous for this allele (P =.005). Compared with women with the Ile/Ile genotype, women who had the Ile/Val or Val/Val genotype had an elevated risk of breast cancer (odds ratio [OR] = 1.4; 95% confidence interval [CI] = 1.0-2.0; P =. 05) after adjustment for age, educational level, study period, history of breast fibroadenoma, leisure physical activity, and age at first live birth. The risk was elevated even more among women who were homozygous for the Val allele (OR = 14.1; 95% CI = 1.8-113.4). The association was more pronounced among younger women (</=45 years) than among older women (>45 years). The adjusted OR associated with the Val allele was 1.7 (95% CI = 1.1-2.6) for younger women and 1.0 (95% CI = 0.5-1.9) for older women.
Conclusions: Results of this study suggest that polymorphisms of the HER2 gene may be important susceptibility biomarkers for breast cancer risk, particularly among younger women.
Comment in
- Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk.
Wang-Gohrke S, Chang-Claude J. Wang-Gohrke S, et al. J Natl Cancer Inst. 2001 Nov 7;93(21):1657-9. doi: 10.1093/jnci/93.21.1657. J Natl Cancer Inst. 2001. PMID: 11698574 No abstract available. - Population-based case-control study of HER2 genetic polymorphism and breast cancer risk.
Chan KY, Cheung AN, Yip SP, Ko HH, Lai TW, Khoo US. Chan KY, et al. J Natl Cancer Inst. 2002 Oct 16;94(20):1581-2. doi: 10.1093/jnci/94.20.1581. J Natl Cancer Inst. 2002. PMID: 12381713 No abstract available. - Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk.
Hishida A, Hamajima N, Iwata H, Matsuo K, Hirose K, Emi N, Tajima K. Hishida A, et al. J Natl Cancer Inst. 2002 Dec 4;94(23):1807-8. doi: 10.1093/jnci/94.23.1807. J Natl Cancer Inst. 2002. PMID: 12464653 No abstract available. - Re: Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk.
Hauptmann M, Sigurdson AJ, Chatterjee N, Rutter JL, Hill DA, Doody MM, Struewing JP. Hauptmann M, et al. J Natl Cancer Inst. 2003 Aug 20;95(16):1251-2. doi: 10.1093/jnci/djg032. J Natl Cancer Inst. 2003. PMID: 12928354 No abstract available.
Similar articles
- The influence of HER2 genotypes as molecular markers on breast cancer outcome.
Mutluhan H, Akbas E, Erdogan NE, Soylemez F, Senli MS, Polat A, Helvaci I, Seyrek E. Mutluhan H, et al. DNA Cell Biol. 2008 Oct;27(10):575-9. doi: 10.1089/dna.2007.0702. DNA Cell Biol. 2008. PMID: 18721072 - Human epithelial growth factor receptor 2[Ile655Val] polymorphism and risk of breast fibroadenoma.
Zubor P, Kajo K, Stanclova A, Szunyogh N, Galo S, Dussan CA, Minarik G, Visnovsky J, Danko J. Zubor P, et al. Eur J Cancer Prev. 2008 Feb;17(1):33-8. doi: 10.1097/CEJ.0b013e3280145e4b. Eur J Cancer Prev. 2008. PMID: 18090908 - Polymorphism and overexpression of HER2/neu among ovarian carcinoma women from Tiruchirapalli, Tamil Nadu, India.
Shanmughapriya S, Senthilkumar G, Arun S, Vinodhini K, Sudhakar S, Natarajaseenivasan K. Shanmughapriya S, et al. Arch Gynecol Obstet. 2013 Dec;288(6):1385-90. doi: 10.1007/s00404-013-2892-y. Epub 2013 May 31. Arch Gynecol Obstet. 2013. PMID: 23722284 - The erbB2/HER2/neu receptor polymorphism Ile655Val and breast cancer risk.
Cox DG, Hankinson SE, Hunter DJ. Cox DG, et al. Pharmacogenet Genomics. 2005 Jul;15(7):447-50. doi: 10.1097/01.fpc.0000166822.66754.c6. Pharmacogenet Genomics. 2005. PMID: 15970791 Review. - Role of HER-2 Ile655Val Polymorphism as Universal Cancer Susceptibility Marker among Different Cancers.
Riaz SK, Rashid MM, Kayani MA, Arshad Malik MF. Riaz SK, et al. Arch Iran Med. 2016 Jun;19(6):430-8. Arch Iran Med. 2016. PMID: 27293060 Review.
Cited by
- Genetic factors in the pathogenesis of cardio-oncology.
Qi Y, Wei Y, Li L, Ge H, Wang Y, Zeng C, Ma F. Qi Y, et al. J Transl Med. 2024 Aug 5;22(1):739. doi: 10.1186/s12967-024-05537-5. J Transl Med. 2024. PMID: 39103883 Free PMC article. Review. - Association of HER1 and HER2 Gene Variants in the Predisposition of Colorectal Cancer.
Alanazi IO, Shaik JP, Parine NR, Azzam NA, Alharbi O, Hawsawi YM, Oyouni AAA, Al-Amer OM, Alzahrani F, Almadi MA, Aljebreen AM, Alanazi MS, Khan Z. Alanazi IO, et al. J Oncol. 2021 Oct 21;2021:6180337. doi: 10.1155/2021/6180337. eCollection 2021. J Oncol. 2021. PMID: 34721579 Free PMC article. - Potential Gene Association Studies of Chemotherapy-Induced Cardiotoxicity: A Systematic Review and Meta-Analysis.
Yang X, Li G, Guan M, Bapat A, Dai Q, Zhong C, Yang T, Luo C, An N, Liu W, Yang F, Pan H, Wang P, Gao Y, Gong Y, Das S, Shang H, Xing Y. Yang X, et al. Front Cardiovasc Med. 2021 Jun 4;8:651269. doi: 10.3389/fcvm.2021.651269. eCollection 2021. Front Cardiovasc Med. 2021. PMID: 34150864 Free PMC article. - Prophylactic Cancer Vaccines Engineered to Elicit Specific Adaptive Immune Response.
Crews DW, Dombroski JA, King MR. Crews DW, et al. Front Oncol. 2021 Mar 29;11:626463. doi: 10.3389/fonc.2021.626463. eCollection 2021. Front Oncol. 2021. PMID: 33869008 Free PMC article. Review. - BCL-2 (-938C>A), BAX (-248G>A), and HER2 Ile655Val Polymorphisms and Breast Cancer Risk in Indian Population.
Bhatt D, Verma AK, Bharti PS, Goyal Y, Alsahli MA, Almatroudi A, Rahmani AH, Almatroodi S, Joshi PC, Alam MM, Ahmad I, Zaman GS, Dev K. Bhatt D, et al. J Oncol. 2021 Feb 25;2021:8865624. doi: 10.1155/2021/8865624. eCollection 2021. J Oncol. 2021. PMID: 33708254 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous